Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 4/20 | 0.34 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.34 |
| ▸ | PTGER2 | P43116 | 4/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 13/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL635958 | 0.82 | PTGER4 (0.40) | PTGER4PTGER3PTGER2P2RX7KMT2A | |
| SCHEMBL2034493 | 0.80 | PTGER4 (0.36) | PTGER4PTGER3PTGER2P2RX7KMT2A | |
| SCHEMBL1866699 | 0.79 | PTGER4 (0.44) | PTGER4PTGER3PTGER2P2RX7KMT2A | |
| SCHEMBL13651410 | 0.77 | PER2 (0.42) | P2RX7KMT2A | |
| SCHEMBL2782894 | 0.77 | PER2 (0.42) | P2RX7KMT2A | |
| SCHEMBL11364946 | 0.76 | PTGER4 (0.48) | PTGER4PTGER3PTGER2KMT2A | |
| SCHEMBL265281 | 0.75 | PTGER3 (0.50) | PTGER4PTGER3PTGER2P2RX7KMT2A | |
| SCHEMBL11949258 | 0.74 | L3MBTL1 (0.39) | P2RX7KMT2AL3MBTL1 | |
| SCHEMBL2037183 | 0.74 | P2RX7 (0.39) | P2RX7 | |
| SCHEMBL11518007 | 0.74 | KMT2A (0.38) | P2RX7KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120136025-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-8133882-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136025-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | P2RY10, P2RY12, P2RY11 | PTGER4 84/4885PTGER3 94/4885PTGER2 169/4885 |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | P2RY12, P2RY11, P2RY10 | PTGER4 100/4885PTGER3 79/4885PTGER2 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.